| Product ID | 72626-2701_3176f9af-1cbb-4c22-a518-75ef434e218b |
| NDC | 72626-2701 |
| Product Type | Human Prescription Drug |
| Proprietary Name | Sofosbuvir and Velpatasvir |
| Generic Name | Velpatasvir And Sofosbuvir |
| Dosage Form | Tablet, Film Coated |
| Route of Administration | ORAL |
| Marketing Start Date | 2018-11-14 |
| Marketing Category | NDA AUTHORIZED GENERIC / NDA AUTHORIZED GENERIC |
| Application Number | NDA208341 |
| Labeler Name | Asegua Therapeutics LLC |
| Substance Name | VELPATASVIR; SOFOSBUVIR |
| Active Ingredient Strength | 100 mg/1; mg/1 |
| Pharm Classes | Organic Anion Transporting Polypeptide 1B1 Inhibitors [MoA],Organic Anion Transporting Polypeptide 1B3 Inhibitors [MoA],Organic Anion Transporting Polypeptide 2B1 Inhibitors [MoA],Hepatitis C Virus NS5A Inhibitor [EPC],Breast Cancer Resistance Protein Inhibitors [MoA],P-Glycoprotein Inhibitors [MoA],Hepatitis C Virus Nucleotide Analog NS5B Polymerase Inhibitor [EPC],RNA Replicase Inhibitors [MoA],Nucleoside Analog [EXT] |
| NDC Exclude Flag | N |
| Listing Certified Through | 2021-12-31 |